The global pulmonary drug delivery systems market size accounted for USD 55.26 billion in 2021 and is projected to cross around USD 92.4 billion by 2030, registering growth at a CAGR of 6.6% during the forecast period 2022 and 2030.
According to the World Health Organization, around 90% of the people breathe pollutant air and around 7 million people die every year due to indoor and outdoor pollution. Moreover, the presence of various key market players and their innovative product launches is impacting the increasing demand for the pulmonary drug delivery devices. For instance, in April 2019, Glenmark Pharmaceuticals Ltd. introduced to latest inhalers – one metered dosed inhale named Soprobec and another breathe actuated inhaler named Stalpex.
Pulmonary Drug Delivery Systems Market Scope
| Report Highlights | Details |
| Market Size | US$ 92.4 Billion by 2030 |
| Growth Rate | CAGR of 6.6% from 2021 to 2030 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Product, Indication, Distribution Channel, Region |
| Companies Mentioned | Philips Respironics, GlaxoSmithKline PLC, BoehringerIngelheim GmbH, TevaPharmaceutical Industries Ltd., 3M Healthcare, PARI GmbH, F. Hoffmann-La Roche AG, Gilbert Technologies, AstraZeneca PLC, Omron Healthcare, Inc. |
Pulmonary Drug Delivery Systems Market Highlights
- Based on the product, the metered dose inhaler segment dominated the market in 2020. The higher product acceptance and increasing prevalence of pulmonary diseases has fueled the growth of this segment. Moreover, the innovative product launches has further boosted the market growth.
- Based on the indication, asthma accounted for the largest market share in 2020. According to the WHO, asthma affects both the adults and children. Changing lifestyle, rapid urbanization, and extended exposure to harmful particles in air are the major reasons behind the increased prevalence of asthma. The higher demand for the pulmonary drug delivery systems for the treatment of asthma has augmented the growth of this segment.
- Based on the distribution channel, the e-commerce is estimated to be the most opportunistic segment during the forecast period. This is attributable to the increasing penetration of the online pharmacies due to the rising adoption of the smartphones and internet across the globe.
Also Read: Generic Injectables Market Size, Outlook 2022 To 2030
Regional Snapshot
North America dominated the global pulmonary drug delivery systems market in 2020. This is attributed to the increased demand for the pulmonary drug delivery devices owing to the increasing prevalence of various pulmonary diseases. As per the Asthma and Allergy Foundation of America, around 25 million people were suffering from asthma in 2018 in US.
Moreover, as per the American Lung Association, around 16.4 million people in US were diagnosed with some type of COPD such as emphysema, chronic bronchitis, and COPD. The increased healthcare expenditure, higher penetration of pharmacies, and better access to the healthcare facilities are the major factors that drives the demand for the pulmonary drug delivery systems in North America.
Asia Pacific is expected to be the fastest-growing market during the forecast period. This is attributed to the increasing air pollution levels in the region. Moreover, the changing lifestyle of the consumers and rapid industrialization is resulting in an alarming rise in the prevalence of the respiratory and pulmonary diseases. According to the World Health Organization, around 80% of the death due to COPD occurs in the low and middle income countries. Therefore, the presence of huge population and rising mortality rates is expected to drive the market growth in Asia Pacific.
Pulmonary Drug Delivery Systems Market Dynamics
Driver: Rise in the prevalence of pulmonary diseases
According to the World Health Organization, around 65 million people across the globe suffers from COPD and around 3 million dies due to it every year. Around 334 million people are suffering from asthma and around 14% of the global children are affected from it. The rising mortality rates and increased awareness regarding the pulmonary diseases is expected to drive the market growth during the forecast period.
Restraint: Stringent government regulations
The strict regulatory scenario and the regulatory requirements of the drug delivery systems is presenting a challenge to the market players because the pulmonary drug delivery systems are a combination of drug and device. Therefore, it is regulated under new provisions by the government.
Opportunity: New product launches
Philips launched a potable mesh nebulizer named InnoSpire Go in 2018. It is a portable, hand-held, and small-sized, and light-weight nebulizer that can administer drugs in just few minutes. Further, Lupin introduced Adhero in 2019. It is a device that tracks the usage pattern of the metered dose inhalers by the COPD patients. Therefore, the frequent product launches with new and innovative features is expected to drive the growth in the future.
Challenge: Lack of access to the healthcare facilities
There is a lack of adequate healthcare infrastructure and lack of access to basic health facilities in the developing and the underdeveloped markets. Most of the people remain undiagnosed and untreated, which may hamper the market growth.
Segments Covered in the Report
By Product
- Dry Powder Inhalers
- Nebulizers
- Metered Dose Inhalers
- Accessories
By Indication
- COPD
- Asthma
- Cystic Fibrosis
- Allergic Rhinitis
- Others
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- E-Commerce
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- South Korea
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of Middle East & Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Pulmonary Drug Delivery Systems Market
5.1. COVID-19 Landscape: Pulmonary Drug Delivery Systems Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Pulmonary Drug Delivery Systems Market, By Product
8.1. Pulmonary Drug Delivery Systems Market, by Product Type, 2021-2030
8.1.1. Dry Powder Inhalers
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Nebulizers
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Metered Dose Inhalers
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Accessories
8.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Pulmonary Drug Delivery Systems Market, By Indication
9.1. Pulmonary Drug Delivery Systems Market, by Indication, 2021-2030
9.1.1. COPD
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Asthma
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Cystic Fibrosis
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Allergic Rhinitis
9.1.4.1. Market Revenue and Forecast (2019-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Pulmonary Drug Delivery Systems Market, By Distribution Channel
10.1. Pulmonary Drug Delivery Systems Market, by Distribution Channel, 2021-2030
10.1.1. Retail Pharmacy
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Hospital Pharmacy
10.1.2.1. Market Revenue and Forecast (2019-2030)
10.1.3. E-Commerce
10.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 11. Global Pulmonary Drug Delivery Systems Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2019-2030)
11.1.2. Market Revenue and Forecast, by Indication (2019-2030)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.1.4.2. Market Revenue and Forecast, by Indication (2019-2030)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.1.5.2. Market Revenue and Forecast, by Indication (2019-2030)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.2. Market Revenue and Forecast, by Indication (2019-2030)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.4.2. Market Revenue and Forecast, by Indication (2019-2030)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.5.2. Market Revenue and Forecast, by Indication (2019-2030)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.6.2. Market Revenue and Forecast, by Indication (2019-2030)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.7.2. Market Revenue and Forecast, by Indication (2019-2030)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.2. Market Revenue and Forecast, by Indication (2019-2030)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.4.2. Market Revenue and Forecast, by Indication (2019-2030)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.5.2. Market Revenue and Forecast, by Indication (2019-2030)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.6.2. Market Revenue and Forecast, by Indication (2019-2030)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.7.2. Market Revenue and Forecast, by Indication (2019-2030)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.2. Market Revenue and Forecast, by Indication (2019-2030)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.4.2. Market Revenue and Forecast, by Indication (2019-2030)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.5.2. Market Revenue and Forecast, by Indication (2019-2030)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.6.2. Market Revenue and Forecast, by Indication (2019-2030)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.7.2. Market Revenue and Forecast, by Indication (2019-2030)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.5.2. Market Revenue and Forecast, by Indication (2019-2030)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.5.4.2. Market Revenue and Forecast, by Indication (2019-2030)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.5.5.2. Market Revenue and Forecast, by Indication (2019-2030)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
Chapter 12. Company Profiles
12.1. Philips Respironics
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. GlaxoSmithKline PLC
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. BoehringerIngelheim GmbH
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. TevaPharmaceutical Industries Ltd.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. 3M Healthcare
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. PARI GmbH
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. F. Hoffmann-La Roche AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Gilbert Technologies
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. AstraZeneca PLC
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Omron Healthcare, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/1502
